Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glucerna REX is a specialized liquid enteral nutritional formula designed for the dietary management of individuals with diabetes mellitus or stress-induced hyperglycemia. Developed and marketed in Japan by Otsuka Pharmaceutical Factory in collaboration with Abbott, it is formulated with a unique slow-release carbohydrate blend that has a low glycemic index to help minimize postprandial blood glucose fluctuations. The product is high in monounsaturated fatty acids (MUFA) and contains dietary fiber and fructooligosaccharides to support gastrointestinal health and improve insulin sensitivity. It is primarily utilized in clinical settings for patients requiring tube feeding or as an oral nutritional supplement to provide balanced nutrition while maintaining stable glycemic control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Glucerna REX.